Ignite Creation Date:
2024-05-05 @ 10:47 PM
Last Modification Date:
2024-10-26 @ 10:24 AM
Study NCT ID:
NCT01185288
Status:
COMPLETED
Last Update Posted:
2014-03-18
First Post:
2010-08-18
Brief Title:
A Study to Determine the Effect of Methotrexate MTX Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis RA Treated With Adalimumab MUSICA
Sponsor:
AbbVie prior sponsor Abbott
Organization:
AbbVie
Study Overview
Official Title:
A Multicenter Double-Blind Randomized Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis Treated With Adalimumab MUSICA
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MUSICA
Brief Summary:
This study will investigate the efficacy of both low and high doses of methotrexate MTX in combination with open-label adalimumab ADA in patients who have had an inadequate response to high dose of MTX The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None